Intravenous Gammaglobulin Treatment in HIV-1 Infection

Deener, Avi; Mehra, Ami; Bernstein, Larry; Shliozberg, Jenny; Rubinstein, Arye

doi:10.1016/j.iac.2008.06.001

Cited by 8 publications

(9 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, IVIG may be useful for preventing bacterial infections, but should not be considered an antiviral therapy in HIVinfected patients. 329 If B-cell function is not restored with immune reconstitution on HAART, there may be implications for the quality anti-polysaccharide antigen responses in particular. Since the advent of HAART, there have been no controlled studies examining the immunomodulatory effects of IVIG in HIVinfected patients taking HAART.…”

Section: Reduction In Viremia In Hiv-infected Individualsmentioning

confidence: 99%

Update on the use of immunoglobulin in human disease: A review of evidence

Perez

Orange

Bonilla

et al. 2017

Journal of Allergy and Clinical Immunology

509

462

View full text Add to dashboard Cite

Human immunoglobulin preparations for intravenous or subcutaneous administration are the cornerstone of treatment in patients with primary immunodeficiency diseases affecting the humoral immune system. Intravenous preparations have a number of important uses in the treatment of other diseases in humans as well, some for which acceptable treatment alternatives do not exist. We provide an update of the evidence-based guideline on immunoglobulin therapy, last published in 2006. Given the potential risks and inherent scarcity of human immunoglobulin, careful consideration of its indications and administration is warranted.

show abstract

Section: Reduction In Viremia In Hiv-infected Individualsmentioning

confidence: 99%

Update on the use of immunoglobulin in human disease: A review of evidence

Perez

Orange

Bonilla

et al. 2017

Journal of Allergy and Clinical Immunology

509

462

View full text Add to dashboard Cite

show abstract

“…In an interesting work Krause et al evaluated the presence of specific antimicrobial activity in 5 commercial kit of IVIg showing that all of these preparations have significant activities against HSV, CMV, VZV, EBV, measles, mumps, rubella, parvovirus B19 [258]. For these reasons, IVIg are employed as a substitute treatment for patients with hypogammaglobulinemia (primary or secondary deficiency] and childhood acquired immunodeficiency syndrome (AIDS) to prevent common opportunistic viral and bacterial infection [259,260]. Many examples in literature were reported about the use of IVIg as prevention or treatment for opportunistic infections in immunocompromised patient secondary to immunosuppressive therapy, AIDS and bone marrow transplantation (BMT).…”

Section: Ivigmentioning

confidence: 99%

The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19

Perricone

Triggianese

Bartoloni

et al. 2020

Journal of Autoimmunity

125

131

View full text Add to dashboard Cite

“…The children presented symptoms that were typical of a B-cell deficiency: recurrent bacterial infections, multiple septic episodes with the same organism, and failure to mount an antibody response to polysaccharide antigens (Deener et al 2008). Treatment of the children with 300 mg/kg IVIG every 2 weeks abolished the recurrent bacterial infections and decreased the level of markers of immune activation such as neopterin and tumor necrosis factor (Deener et al 2008). In a 10-year followup of 112 children, ages 9 months to 6 years treated with this regimen, there were no episodes of sepsis and only mild upper respiratory infections.…”

Section: Hiv Infectionmentioning

confidence: 99%

“…No controlled studies have documented the effect of IVIG on patients who are infected with HIV-1 and are on HAART. Thus the role of IVIG in the post-HAART era is controversial (Deener et al 2008). …”

Section: Hiv Infectionmentioning

confidence: 99%

The history and evolution of immunoglobulin products and their clinical indications

Hooper¹

2015

LymphoSign Journal

View full text Add to dashboard Cite

The history of providing antibodies to treat diseases began in the 19th century with the discovery of tetanus and diphtheria toxins and the demonstration that immunity to tetanus and diphtheria infections could be transferred by immune sera. Characterization of the mediators of this immunity resulted in the discovery that antibodies are proteins that can be isolated and used to protect against infectious diseases. Development of a method to isolate antibodies from human plasma that could be safely injected into people initiated the development of human gamma globulin preparations to provide antibodies to patients with inherited antibody deficiencies. To overcome the limitations imposed by intramuscular injection of gamma globulin, intravenous gamma globulin preparations were developed that began to be used in a wide variety of clinical conditions. Thus the original clinical indication for infection prevention was expanded to several other indications that employ large doses to suppress inflammatory and autoimmune disorders. The most recent development in immunoglobulin therapy is the production of concentrated immune globulins for subcutaneous injection. Home infusions of subcutaneous immunoglobulin are increasingly used to treat immunodeficient patients and are being studied for other clinical applications.

show abstract

Intravenous Gammaglobulin Treatment in HIV-1 Infection

Cited by 8 publications

References 50 publications

Update on the use of immunoglobulin in human disease: A review of evidence

Update on the use of immunoglobulin in human disease: A review of evidence

The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19

The history and evolution of immunoglobulin products and their clinical indications

Contact Info

Product

Resources

About